ASLAN Pharmaceuticals (ASLN) Competitors $0.60 0.00 (0.00%) As of 10/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock ASLN vs. ONCO, XBIO, APVO, BDRX, SHPH, ADTX, TRIB, DRMA, REVB, and SPRCShould you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Onconetix (ONCO), Xenetic Biosciences (XBIO), Aptevo Therapeutics (APVO), Biodexa Pharmaceuticals (BDRX), Shuttle Pharmaceuticals (SHPH), Aditxt (ADTX), Trinity Biotech (TRIB), Dermata Therapeutics (DRMA), Revelation Biosciences (REVB), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. ASLAN Pharmaceuticals vs. Its Competitors Onconetix Xenetic Biosciences Aptevo Therapeutics Biodexa Pharmaceuticals Shuttle Pharmaceuticals Aditxt Trinity Biotech Dermata Therapeutics Revelation Biosciences SciSparc ASLAN Pharmaceuticals (NASDAQ:ASLN) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Does the media favor ASLN or ONCO? In the previous week, Onconetix had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score. Company Overall Sentiment ASLAN Pharmaceuticals Neutral Onconetix Neutral Is ASLN or ONCO more profitable? ASLAN Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Onconetix's return on equity of -192.74% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ASLAN PharmaceuticalsN/A -8,454.87% -121.60% Onconetix -3,327.03%-192.74%-89.55% Do analysts prefer ASLN or ONCO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher earnings & valuation, ASLN or ONCO? ASLAN Pharmaceuticals has higher revenue and earnings than Onconetix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03Onconetix$2.52M1.92-$58.69MN/AN/A Which has more risk and volatility, ASLN or ONCO? ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.39, meaning that its stock price is 239% more volatile than the S&P 500. Do insiders & institutionals believe in ASLN or ONCO? 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryOnconetix beats ASLAN Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASLN vs. The Competition Export to ExcelMetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$1.01B$6.08B$10.54BDividend YieldN/A4.84%5.68%4.70%P/E Ratio-0.031.2578.0526.71Price / Sales0.1025.34579.79179.45Price / CashN/A17.6537.7961.25Price / Book-0.096.9612.556.56Net Income-$44.22M-$5.93M$3.31B$277.70M7 Day PerformanceN/A2.07%4.28%2.41%1 Month PerformanceN/A4.52%7.85%9.30%1 Year PerformanceN/A42.08%71.37%31.22% ASLAN Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330ONCOOnconetix0.7887 of 5 stars$3.11-3.1%N/A-99.2%$4.82M$2.52M0.0012Gap DownXBIOXenetic Biosciences0.7009 of 5 stars$3.13-3.4%N/A-28.0%$4.82M$2.50M-1.574APVOAptevo Therapeutics1.8308 of 5 stars$1.45+0.7%N/A-100.0%$4.77M$3.11M0.0050Short Interest ↓BDRXBiodexa Pharmaceuticals0.1963 of 5 stars$6.65-0.6%N/AN/A$4.12M$470K0.0020News CoverageShort Interest ↑SHPHShuttle Pharmaceuticals0.212 of 5 stars$3.55-6.6%N/A-84.7%$3.80MN/A-0.865Gap UpADTXAditxtN/A$0.75-8.8%N/A-99.8%$3.75M$130K0.0060News CoverageShort Interest ↓TRIBTrinity Biotech1.3329 of 5 stars$1.04-1.0%N/A-80.2%$3.74M$61.56M-0.07480News CoveragePositive NewsShort Interest ↓DRMADermata Therapeutics2.3088 of 5 stars$5.02-3.5%$10.00+99.2%-65.2%$3.41MN/A-0.318News CoveragePositive NewsREVBRevelation Biosciences1.639 of 5 stars$1.42-0.7%N/A-96.2%$3.32MN/A-0.0210Positive NewsShort Interest ↓SPRCSciSparc0.8905 of 5 stars$6.04+35.4%N/A+2.8%$3.23M$1.31M0.004Gap UpHigh Trading Volume Related Companies and Tools Related Companies ONCO Alternatives XBIO Alternatives APVO Alternatives BDRX Alternatives SHPH Alternatives ADTX Alternatives TRIB Alternatives DRMA Alternatives REVB Alternatives SPRC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASLN) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASLN Stock Alerts